Where is Jian Li headquartered?

Jian Li is recorded with headquarters in CN in NovaPharmaNews public regulatory and sponsor datasets.

Is Jian Li publicly traded?

Jian Li is represented in our database primarily through regulatory marketing authorisation or trial sponsor records; it may not have a US listed ticker in SEC EDGAR.

What drugs are associated with Jian Li?

No drug profiles are currently linked to Jian Li; check pipeline programs or search the drug directory.

What clinical trials is Jian Li sponsoring?

Jian Li is linked to 28 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Jian Li as applicant?

No US patent records are currently linked to this company profile.

What pipeline phases does Jian Li have in our database?

Phase distribution from linked programs: phase 1: 14, phase 2: 5, phase 3: 4, approved: 1.

Where does NovaPharmaNews source data on Jian Li?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Jian Li data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Jian Li data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Jian Li data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

LianBio Pharmaceuticals Company Profile | Pipeline, Drugs, Clinical…

Name: LianBio intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: CN
Founded: 2019
Employees: 47
Programs: 28
Drugs: 40
Patents: 0

Official website ↗ All projects Drug pipeline News & analysis

Quick answer

Jian Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Kidney Dysfunction, Obesity, Fibrosis, Ebola Virus Disease, Bladder Cancer. NovaPharmaNews links 28 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (14), phase 2 (5), phase 3 (4).

Company snapshot

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and other major Asian markets through partnerships that provide access to innovative therapeutic discoveries.

28 active pipeline program(s) linked via ClinicalTrials.gov.
28 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for LianBio. Not investment advice.

Top assets

View drugs (40) View projects (28)

Lead pipeline drugs

626
Marketed / approved
[14c]absk011
Marketed / approved
acetic acid, glacial
approved
anti-
Marketed / approved

Active clinical programs

HS-20094 Injection Type 2 Diabetes
Phase 3
Irinotecan liposome、5-Fluorouracil、Leucovorin Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Phase 3
Placebos Advanced Non-small Cell Lung Cancer
Phase 3
SHR-1210 Locally Advanced or Metastatic and Unresectable HCC
Phase 3

Momentum

Proprietary activity score for LianBio.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 28 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Hospital Authority

TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for LianBio.

Jun 8, 2026 Clinical update
Radiotherapy combined with TKI and Anti-PD-1 Antibody — Unknown
Jun 8, 2026 Clinical update
Placebos — Phase 3
Jun 8, 2026 Clinical update
Part1:Recombinant two-component COVID-19 vaccine (CHO cell) — Phase 2
Jun 8, 2026 Clinical update
Karelizumab combined with etoposide and cisplatin — Phase 2
Jun 8, 2026 Clinical update
Irinotecan liposome、5-Fluorouracil、Leucovorin — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is LianBio?

Jian Li is a pharma organization headquartered in CN. Primary therapeutic focus areas include Kidney Dysfunction, Obesity, Fibrosis, Ebola Virus Disease, Bladder Cancer. NovaPharmaNews links 28 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from pub
Is LianBio publicly traded?

LianBio appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.
What drugs does LianBio develop or market?

We link 40 drug profile(s) where LianBio is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/jian-li#company-drugs.
What are the latest developments for LianBio?

In the last 12 months our linked public records show 28 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does LianBio focus on?

LianBio focuses on Kidney Dysfunction, Obesity, Fibrosis based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Oncology

Infectious Disease

Neurology

Quick answer

Company snapshot

Top assets

Lead pipeline drugs

Active clinical programs

Momentum

Signal breakdown

Competitor landscape

Recent activity

Quick answers

Therapeutic area distribution

Programs by therapeutic area

Stay Ahead in Pharma